showed that activation of the metabolic sensor AMPK through the administration of N6‐isopentenyladenosine (iPA) inhibited the in vivo growth of GBM tumors, with markedly enhanced efficacy in cells with higher levels of EGFR expression/activity (18). The gene discussed is EGFR; the disease is glioblastoma.